Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment
Status:
Not yet recruiting
Trial end date:
2023-10-15
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the efficacy and safety of stereotactic body
radiation therapy (SBRT) combined neoadjuvant treatment for patients with triple-negative and
hormone receptor-positive, HER2-negative breast cancer